Crinetics Pharmaceuticals (CRNX)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$0.52 (+0.92%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Crinetics Pharmaceuticals (CRNX)
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.

Key Insights

Critical company metrics and information

  • Share Price

    $57.11

  • Market Cap

    $5.30 Billion

  • Total Outstanding Shares

    92.74 Million Shares

  • Total Employees

    210

  • Dividend

    No dividend

  • IPO Date

    July 18, 2018

  • SIC Description

    Pharmaceutical Preparations

  • Homepage

    https://www.crinetics.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow From Operating Activities$-199.81 Million
Net Cash Flow From Financing Activities$494.32 Million
Net Cash Flow From Investing Activities, Continuing$-120.04 Million
Net Cash Flow From Financing Activities, Continuing$494.32 Million
Net Cash Flow From Investing Activities$-120.04 Million
Net Cash Flow, Continuing$174.47 Million
Net Cash Flow From Operating Activities, Continuing$-199.81 Million
Net Cash Flow$174.47 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Operating Expenses$307.81 Million
Income/Loss From Continuing Operations After Tax$-277.91 Million
Income/Loss From Continuing Operations Before Tax$-294.33 Million
Diluted Average Shares$158.85 Million
Operating Income/Loss$-306.77 Million
Benefits Costs and Expenses$218.54 Million
Basic Average Shares$158.85 Million
Research and Development$219.17 Million
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Nonoperating Income/Loss$33.53 Million
Other Operating Expenses$87.15 Million
Net Income/Loss$-277.91 Million
Net Income/Loss Attributable To Parent$-277.91 Million
Basic Earnings Per Share$3.70
Revenues$1.04 Million
Preferred Stock Dividends And Other Adjustments$0.00
Depreciation and Amortization$2.26 Million
Costs And Expenses$299.73 Million
Diluted Earnings Per Share$3.70
Net Income/Loss Available To Common Stockholders, Basic$-277.91 Million

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Current Assets$877.59 Million
Assets$937.37 Million
Other Non-current Assets$48.08 Million
Equity Attributable To Noncontrolling Interest$0.00
Equity Attributable To Parent$832.98 Million
Noncurrent Liabilities$50.83 Million
Current Liabilities$53.56 Million
Fixed Assets$11.71 Million
Cash$862.70 Million
Liabilities$104.39 Million
Other Current Assets$14.89 Million
Noncurrent Assets$59.79 Million
Equity$832.98 Million
Liabilities And Equity$937.37 Million
Other Current Liabilities$48.62 Million
Accounts Payable$4.94 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
Earnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

â“’ 2024 Financhle. All Rights Reserved.